Can I invest in SIP and Lumpsum in Nippon India Pharma Fund (G) Direct Growth?

Yes, you can invest both lumpsum and SIP in Nippon India Pharma Fund (G). Minimum lumpsum investment Nippon India Pharma Fund (G) is ₹5,000 and minimum SIP amount is ₹100 . Lumpsum option is ideal for investors with higher investible corpus and market experience. SIP option is recommended for retail investors who do not have the time or expertise to time the market.

What is the NAV of Nippon India Pharma Fund (G) Direct Growth?

The latest NAV (Net Asset Value) of Nippon India Pharma Fund (G) is Nippon India Pharma Fund (G) is ₹467.98 as on 2025-03-07.

Which are the biggest stock holdings of Nippon India Pharma Fund (G)?

The 5 biggest stock holdings of Nippon India Pharma Fund (G) are: Sun Pharma.Inds. (13.68%), Divi's Lab. (9.32%), Lupin (7.73%), Cipla (5.90%), Dr Reddy's Labs (5.35%)

What are the top sectors Nippon India Pharma Fund (G) invests in?

A majority of Nippon India Pharma Fund (G) 's AUM worth ₹7,637.04 (Cr) is invested in these 3 top sectors: Pharmaceuticals & Biotech : 76.55% Healthcare Services : 18.94% Retailing : 3.16%

Mutual Funds
Nippon India Pharma Fund (G)

Nippon India Pharma Fund (G)

Sectoral / Thematic

Invest Now

NAV
467.98(-0.11%)
Fund Size (CR)
₹8,160.74
Expense Ratio
1.82
Scheme Type
Active Fund
Value Research

Min. investment
₹5,000
Minimum Additional Investment
₹1,000
Minimum SIP Investment
₹100
Minimum Withdrawal
₹100
Exit Load
1% of applicable Net Asset Value - If the amount sought to be redeemed or switch out is invested for a period of up to 3 months from the date of allotment Nil - If the amount, sought to be redeemed or switch out is invested for a period of more than 3 months from the date of allotment
1%
Return Since Launch
20.34%

Absolute Return: -8.85%

Annualized Return: 0%

Basic Details

Scheme Manager

Sailesh Raj Bhan

Bench Mark

BSE Healthcare TRI

Type

OPEN

Lumpsum Returns

Period Invested For	₹10,000 Invested on	Latest Value	Absolute Returns	Annualised Returns	Category Avg	Rank within Category
1 Week	28 February 2025	10357.85	3.58%	-	3.03%	291/862
1 Month	7 February 2025	9415.55	-5.84%	-	-6.13%	373/834
3 Month	6 December 2024	9054.08	-9.46%	-	-12.94%	123/790
6 Month	6 September 2024	8994.21	-10.06%	-	-12.68%	214/739
1 Year	7 March 2024	10924.06	9.24%	9.24%	3.66%	110/662
3 Year	7 March 2022	17239.19	72.39%	19.89%	18.58%	209/482
5 Year	6 March 2020	29191.65	191.92%	23.87%	20.60%	145/396
Since Inception	5 June 2004	467978.40	4579.78%	20.34%	9.72%	98/862

Note: Lumpsum Returns since Inception Date.

SIP Returns

Period Invested For	₹10,000 Invested on	Investments	Latest Value	Absolute Returns	Annualised Returns
1 Year	1 April 2024	1,20,000	117575.55	-2.02%	-2.02%
3 Year	1 April 2022	3,60,000	484530.03	34.59%	10.41%
5 Year	1 April 2020	6,00,000	945855.52	57.64%	9.53%
10 Year	1 April 2015	12,00,000	2930871.67	144.24%	9.34%

Note: SIP Returns since Inception Date.

Tax Treatment

If sold after 1 year from purchase date, long term capital gain tax will be applicable. Current tax rate is 10%, if your total long term capital gain exceeds 1 lakh. Any cess/surcharge is not included.If sold before 1 year from purchase date, short term capital gain tax will be applicable. Current tax rate is 15%. Any cess/surcharge is not included in the 15%.

Mutual Funds Calculator

Investment type
Scheme based

SIP
Lumpsum

Monthly Investment (₹)

Expected Returns Rate (%)

Time Period (in Years)

Start your SIP now

Invested Amount
₹25,000
Estimated Returns
₹19,059

76%

Returns

Future value of your investment

₹44,059

Risk Ratios

4.51%

Standard Deviation

0.76%

Beta

0.70%

Sharpe Ratio

0.02%

Treynor's Ratio

8.48%

Jension's Alpha

Asset Allocation

Sector Allocation

Top 10 stock holding in portfolio

Stock Invested in	% of Total Holdings	Quantity	Value (Cr)	Asset Type	Segment
Sun Pharma.Inds.	13.68%	6556349	1044.59	Equity	Pharmaceuticals
Divi's Lab.	9.32%	1298808	711.78	Equity	Pharmaceuticals
Lupin	7.73%	3098126	590.08	Equity	Pharmaceuticals
Cipla	5.90%	3200000	450.40	Equity	Pharmaceuticals
Dr Reddy's Labs	5.35%	3662170	408.88	Equity	Pharmaceuticals
Apollo Hospitals	5.14%	648795	392.69	Equity	Healthcare
Abbott India	3.82%	95985	291.75	Equity	Pharmaceuticals
Vijaya Diagnost.	3.41%	2843231	260.37	Equity	Healthcare
Medplus Health	3.39%	3627277	259.21	Equity	Retail
Glaxosmi. Pharma	3.28%	1011921	250.49	Equity	Pharmaceuticals

Peer Comparison

Scheme Name	Asset Size (Cr)	1M	3M	6M	1Y	3Y
HDFC Pharma and Healthcare Fund - Direct (G)	1568.02	-7.85%	-8.25%	-4.03%	25.42%	-
HDFC Pharma and Healthcare Fund - Direct (IDCW)	1568.02	-7.85%	-8.25%	-4.03%	25.42%	-
WhiteOak Capital Pharma and Healthcare Fund-Dir (G)	285.76	-8.50%	-9.13%	-4.25%	24.37%	-
SBI Healthcare Opportunities Fund - Direct (G)	3521.93	-6.71%	-7.62%	-3.25%	18.88%	25.65%
SBI Healthcare Opportunities Fund - Direct (IDCW)	3521.93	-6.71%	-7.62%	-3.25%	18.88%	25.65%

News

Nippon India Mutual Fund Income Distribution cum Capital Withdrawal (IDCW)
Nippon India Mutual Fund has announced 06 March 2025 as the record date for declaration of Income Distribution cum Capital Withdrawal (IDCW) under the following schemes. The amount of distribution (Rs per unit) on the face value of Rs 10 per unit will be:
Nippon India ELSS Tax Saver Fund ' Regular Plan ' Annual IDCW Option Regular & Direct Plan ' IDCW Option: 1.50 each.
Nippon India ELSS Tax Saver Fund ' Regular Plan ' IDCW Option: 2.50
Nippon India ELSS Tax Saver Fund ' Direct Plan ' IDCW Option: 3.00
Powered by Capital Market - Live News

Nippon India Mutual Fund Income Distribution cum Capital Withdrawal (IDCW)
Nippon India Mutual Fund has announced 03 March 2025 as the record date for declaration of Income Distribution cum Capital Withdrawal (IDCW) under the following schemes. The amount of distribution (Rs per unit) on the face value of Rs 10 per unit will be:
Nippon India Equity Hybrid Fund ' Regular Plan ' IDCW Option & Direct Plan ' IDCW Option: 2.00 each.
Nippon India Equity Hybrid Fund ' Regular Plan ' Monthly IDCW Option & Direct Plan ' Monthly IDCW Option: 1.00 each
Nippon India Equity Hybrid Fund ' Regular Plan ' Quarterly IDCW Option: 1.75
Nippon India Equity Hybrid Fund ' Direct Plan ' Quarterly IDCW Option: 2.00
Powered by Capital Market - Live News

Nippon India Balanced Advantage Fund announces Income Distribution cum Capital Withdrawal (IDCW)
Nippon India Mutual Fund has announced 14 February 2025 as the record date for declaration of Income Distribution cum Capital Withdrawal (IDCW) on the face value of Rs 10 per unit under the regular plan ' IDCW payout and direct plan ' IDCW payout of Nippon India Balanced Advantage Fund. The quantum of distribution will be Rs 0.2000 per unit under each plan / option as on the record date.
Powered by Capital Market - Live News

Fund House Details & Investment Objective

Date of Incorporation

10 May 2004

Total AUM (Cr)

₹7637.04

Nippon India Pharma Fund (G) is an Sectoral / Thematic-oriented fund from the renowned AMC, Nippon India Mutual Fund. Launched in 10 May 2004, this fund is managed by Sailesh Raj Bhan. With assets under management (AUM) worth ₹7,637.04 (Cr), as of 7 March 2025, Nippon India Pharma Fund (G) is categorized as a Sectoral / Thematic within its segment. The fund has generated a return of 20.34% since its launch.
The current NAV of Nippon India Pharma Fund (G) is ₹467.98, as on 7 March 2025. The fund's benchmark index is BSE Healthcare TRI. You can invest in Nippon India Pharma Fund (G) via both lumpsum and SIP modes. The minimum SIP amount in the fund is ₹100 while the minimum lumpsum investment is ₹5,000.

Being an open-ended fund, you can exit the fund anytime subject to applicable exit loads:
1% if redeemed or switchd out on or before completion of 1 Months from the date of allotment of units. NIl if redeemed or switched out after the completion of 1 Months from the date of allotment of units. The fund has generated 19.89% and 23.87% CAGR in the last 3 and 5 years respectively.

The fund aims to provide long-term capital appreciation and growth, by investing in a mix of financial instruments 98.88% in Equity, 1.32% in Debt and -0.20% in cash and cash equivalents.
The top 5 sectors the fund invests in are: 76.55% in Pharmaceuticals & Biotech, 18.94% in Healthcare Services, 3.16% in Retailing, 1.49% in Debt, -0.14% in Cash & Others

FAQs

How to Invest in Nippon India Pharma Fund (G) Direct Growth?

Nippon India Pharma Fund (G) is a popular fund in the Sectoral / Thematic segment. The fund has generated a return of 20.34% since inception. Looking to invest in Nippon India Pharma Fund (G) How about earning 1% extra return? All this is possible with m.Stock! Investing in Nippon India Pharma Fund (G) is super easy and convenient with m.Stock. Here’s how you can begin:

Login to your m.Stock account. If you do not have an account, open m.Stock Demat account and enjoy 1% extra returns plus Zero Brokerage across products for life.
In the ‘Menu’ section, under ‘Products’, select ‘Mutual Funds’ .
In the search bar, enter the fund name, in this case, Nippon India Pharma Fund (G)
On the top right corner you’ll see two options – Lumpsum and SIP. You can choose either based on your risk appetite and available investible corpus.
If you choose to invest a Lumpsum: Enter amount, select payment mode (UPI or Netbanking), and click on ‘invest a lumpsum’. Make the payment and your lumpsum investment is complete.
If you choose the SIP route, then enter SIP amount, SIP date, and set up ‘Autopay’ facility.

So, why wait? Invest in Nippon India Pharma Fund (G) today and reap the benefits of this Sectoral / Thematic fund!

How much returns has Nippon India Pharma Fund (G) Direct Growth generated?

In the short term, i.e., 1 year, Nippon India Pharma Fund (G) has generated annualised return of 9.24%. In the long-term, the fund has generated 19.89% and 23.87% in 3 and 5 years respectively. Since its inception, the fund has generated 20.34% returns.

What is the expense ratio of Nippon India Pharma Fund (G) Direct Growth?

The expense ratio of Nippon India Pharma Fund (G) Direct Growth is 1.82%. Expense ratio is the fees payable by investors of the scheme towards management, research and overall upkeep of the fund. The higher the expense ratio, the lower is the in-hand return for the investor. Expense ratio for direct plans is lower than regular plans, making them ideal for investors.

What is the AUM of Nippon India Pharma Fund (G) Fund Direct Growth?

The Assets Under Management (AUM) of Nippon India Pharma Fund (G) is ₹7,637.04 (Cr) as of 2025-03-07 AUM shows the fund’s popularity and is often indicative of fund strength.

How to redeem or withdraw money from Nippon India Pharma Fund (G) Direct Growth?

Redeeming or selling units of Nippon India Pharma Fund (G) is relatively simple. But before you redeem, ensure that the fund has completed the minimum lock-in period else you will be charged an exit load.

To redeem from Nippon India Pharma Fund (G):

Login to your m.Stock account
In portfolio, your mutual fund investments will be visible under ‘MF’
Select the fund you wish to redeem from (in this case Nippon India Pharma Fund (G)).
Click on ‘Redeem’ button
You have 2 options – redeem by units and redeem by value (you can only redeem free units)
Select units to be redeemed and click on submit.
Redemption value will be credited to your account in 2-3 working days (as per timelines set by SEBI).